New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 9, 2014
09:13 EDTCOH, LXRX, SLXP, AVAV, RAI, AAL, CELG, GRMN, MSM, BOBE, GIMO, BP, KKR, SDRL, SIMG, LO, TCSOn The Fly: Pre-market Movers
HIGHER: American Airlines (AAL), up 5.5% after reporting its June traffic rose 1%, forecasting its 2014 total system capacity to be up 3% from last year... AeroVironment (AVAV), up 5.5% after reporting better than expected Q4 earnings results... Reynolds American (RAI), up 1.3% after Daily Mail reported that British American Tobacco (BTI) is rumored to be near a deal to buy out the stake in Reynolds it does not already own, which would prevent a Reynolds takeover of Lorillard (LO). Lorillard shares are down 1.4% in pre-market trade following the report... Lexicon (LXRX), up 11.5% after announcing JDRF, the world's largest non-profit supporter of type 1 diabetes research, will provide funding to support a Phase 2 trial to evaluate the efficacy and safety of LX4211... Seadrill (SDRL), up 3% after cancelling contemplated convertible bond issuance... KKR (KKR), up 1.3% after upgraded to Outperform at Credit Suisse. DOWN AFTER EARNINGS: Container Store (TCS), down 15%... Bob Evans (BOBE), down 1.2%... MSC Industrial (MSM), down 3%. ALSO LOWER: Gigamon (GIMO), down 32% following downgrades at five firms after the company lowered its Q2 revenue guidance... Garmin (GRMN), down 2.7% following downgrade at Pacific Crest... Silicon Image (SIMG), down 11% after cutting second quarter guidance... Salix (SLXP), down 4% after announcing deal to combine with Cosmo Technologies... Celgene (CELG), down 1.5% after OTEZLA did not achieve primary endpoint in Phase III trial... Coach (COH), down 0.7% following downgrade at Buckingham... BP (BP), down 1% after downgraded at Deutsche Bank.
News For AAL;TCS;GIMO;RAI;LO;BOBE;AVAV;SIMG;MSM;SLXP;SDRL;GRMN;LXRX;KKR;CELG;COH;BP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
March 23, 2015
06:06 EDTKKRAres Management, GE Capital invests in package supporting KKR acquisition
Subscribe for More Information
05:55 EDTCELGStocks with implied volatility movement; AMZN CELG
Subscribe for More Information
March 22, 2015
17:59 EDTBPOPEC will not take sole responsibility for supporting oil price, Reuters says
Subscribe for More Information
March 20, 2015
16:33 EDTSLXPStocks end week higher after market reads Fed statement as dovish
Subscribe for More Information
15:25 EDTSDRLSeadrill volatility at three-month low
Subscribe for More Information
13:04 EDTCELGCelgene reports results from long-term efficacy,safety analyses of Otezla trials
Celgene announced that results from long-term efficacy and safety analyses of the ESTEEM phase III clinical trial program of Otezla were presented at the 73rd Annual Meeting of the American Academy of Dermatology. OTEZLA is the company’s oral, selective inhibitor of phosphodiesterase 4 approved for the treatment of patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy and for the treatment of adults with active psoriatic arthritis. In ESTEEM 1 and 2, patients were randomized to treatment with OTEZLA 30 mg twice daily or placebo for the first 16 weeks. At week 16, patients either continued on OTEZLA or were switched from placebo to OTEZLA 30 mg twice daily through week 32. Patients initially randomized to OTEZLA who achieved a Psoriasis Area and Severity Index-75 response or PASI-50 response at week 32 were then re-randomized to either OTEZLA 30 mg twice daily or placebo. Celgene said improvements in the severity of preexisting nail, scalp and palmoplantar psoriasis achieved at week 16 were maintained in OTEZLA responders through week 52 in ESTEEM 2; OTEZLA improved the severity of palmoplantar psoriasis at week 16 in a subset of patients across three trials; Long-term safety profile for up to 104 weeks in ESTEEM 1 was consistent with previously reported data from OTEZLA clinical trial programs, with no new safety signals and no clinically meaningful changes in laboratory values.
13:01 EDTCELGCelgene announces positive Phase III study results evaluating Otezla
Celgene announced that results from its ongoing phase III LIBERATE trial evaluating Otezla, the company’s oral, selective inhibitor of phosphodiesterase 4, in patients with moderate to severe plaque psoriasis. The LIBERATE study evaluated the clinical efficacy and safety of either oral OTEZLA 30 mg twice daily or weekly subcutaneous etanercept 50 mg compared with placebo at week 16 in 250 patients who had no prior exposure to a biological therapy. It also examined the relative safety of a switch from etanercept to OTEZLA after week 16. At week 16, patients receiving OTEZLA 30 mg twice daily demonstrated statistically significant and clinically meaningful improvement when compared with placebo, as measured by the Psoriasis Area and Severity Index-75 response. At week 16, statistical significance was also achieved for patients receiving weekly injections of etanercept 50 mg when compared with placebo. A post-hoc analysis revealed no significant difference between OTEZLA and etanercept in PASI-75 at week 16. LIBERATE was not designed or powered to directly compare OTEZLA to etanercept.
10:51 EDTCELGStocks with call strike movement; DAL CELG
Delta Air Lines (DAL) September 57.5 call option implied volatility decreased 1% to 34, Celgene (CELG) July 145 call option implied volatility increased 3% to 28 according to IVolatility.
10:18 EDTSLXPOptions with decreasing implied volatility
Options with decreasing implied volatility: NKTR FOLD RUSL RSX ORCL GES CTRP SLXP WSM SPXS
09:45 EDTCELGActive equity options trading on open
Subscribe for More Information
09:04 EDTGIMOGigamon's GigaVUE added to approved product list for Defense Dept
Subscribe for More Information
07:41 EDTCELGAmerican Academy of Dermatology to hold annual meeting
Subscribe for More Information
07:19 EDTBPWhite House expected to unveil fracking rules today, WSJ says
Subscribe for More Information
06:37 EDTBPOil prices fall again, Reuters reports
Subscribe for More Information
06:26 EDTCELGCelgene price target raised to $144 from $135 at Piper Jaffray
Subscribe for More Information
March 19, 2015
15:46 EDTKKRKKR, CVC near deal for majority of Philips lighting unit, Bloomberg says
Private equity firms KKR (KKR) and CVC Capital Partners are nearing a deal that could be announced as soon as next week to buy 80% of Philips' (PHG) lighting components unit, with Philips retaining the remaining stake, reported Bloomberg, citing people with knowledge of the matter. The firms' bid values the whole of the business at about $2.7B, the sources told Bloomberg. Reference Link
15:19 EDTKKRKKR, CVC near bid for 80% of Philips lighting components unit, Bloomberg says
Subscribe for More Information
10:42 EDTSLXPOptions with decreasing implied volatility
Subscribe for More Information
09:37 EDTCELGActive equity options trading on open
Subscribe for More Information
07:19 EDTBPKuwaiti minister says OPEC can't cut oil production, Bloomberg reports
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use